CLL
News
ESMO offers new clinical practice guideline for CLL
Article
Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies
News
Two new protein biomarkers may serve as prognostic indicators for outcomes in CLL
Study also validated the prognostic value of two previously studied biomarkers.
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
News
Oxidative stress linked to cytogenetic abnormalities in CLL
News
Antihistamines synergistically induce CLL cell death with TK inhibitors
Over-the-counter antihistamines induced synergistic cytotoxicity with TK inhibitors.
News
BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients
News
EMA gives green light to avapritinib for GIST, acalabrutinib for CLL
The Committee for Medicinal Products for Human Use has given a favorable opinion on both drugs.
News
In remission for 10 years: Long-term toxicity data on CAR T cells
Conference Coverage
Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL
Minimal residual disease was undetectable in peripheral blood of 75% of patients after an ibrutinib lead-in and 12 cycles of the combination.